Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSNASDAQ:BLRXNASDAQ:NTECNASDAQ:NTRPNASDAQ:PRAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.12$0.06$0.00▼$0.78$5.13M1.175,773 shs6 shsBLRXBioLineRx$4.63+0.4%$4.11$2.30▼$35.60$19.72M1.25234,004 shs36,037 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shsNTRPNextTrip$3.55-6.3%$0.96$0.68▼$3.85$27.17M1.5428,100 shs22,300 shsPRANAlterity Therapeutics$4.15+2.6%$1.41$1.09▼$2.91$36.94M1.05130,956 shs11,274 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%+343.91%+263.44%+301.00%-38.15%BLRXBioLineRx0.00%+4.51%-19.34%+83.73%-78.82%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%NTRPNextTrip0.00%+1.14%+25.44%-33.27%+68.25%PRANAlterity Therapeutics0.00%+5.51%-13.74%+41.50%+127.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABLRXBioLineRx2.6951 of 5 stars3.83.00.00.03.00.00.6NTECIntec PharmaN/AN/AN/AN/AN/AN/AN/AN/ANTRPNextTrip1.823 of 5 stars3.03.00.00.01.10.01.3PRANAlterity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/ABLRXBioLineRx 3.50Strong Buy$26.00461.56% UpsideNTECIntec Pharma 0.00N/AN/AN/ANTRPNextTrip 2.00Hold$5.0040.85% UpsidePRANAlterity Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRAN, BLRX, NTEC, NTRP, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M1.58N/AN/A($2.06) per share-0.06BLRXBioLineRx$28.94M0.68N/AN/A$4.04 per share1.15NTECIntec PharmaN/AN/AN/AN/A$16.18 per shareN/ANTRPNextTrip$500K54.32N/AN/A$4.16 per share0.85PRANAlterity Therapeutics$150K246.23N/AN/A$1.40 per share2.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/ABLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/21/2025 (Estimated)NTECIntec Pharma-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/ANTRPNextTrip-$10.12MN/A0.0029.58N/A-2,015.64%-580.52%-165.33%N/APRANAlterity Therapeutics-$6.40M-$0.70N/A∞N/AN/AN/AN/AN/ALatest PRAN, BLRX, NTEC, NTRP, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/ANTRPNextTripN/AN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/ABLRXBioLineRx0.372.272.04NTECIntec PharmaN/A2.342.34NTRPNextTripN/A0.960.96PRANAlterity TherapeuticsN/A4.37N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%BLRXBioLineRx1.56%NTECIntec Pharma22.37%NTRPNextTrip3.81%PRANAlterity Therapeutics3.63%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%BLRXBioLineRx1.10%NTECIntec Pharma3.30%NTRPNextTrip9.60%PRANAlterity Therapeutics38.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableBLRXBioLineRx404.26 million4.22 millionOptionableNTECIntec Pharma40898,000N/AOptionableNTRPNextTrip57.65 million6.92 millionNo DataPRANAlterity Therapeutics148.90 millionN/ANot OptionablePRAN, BLRX, NTEC, NTRP, and ADXS HeadlinesRecent News About These CompaniesASX:ATH Financials | Alterity Therapeutics Ltd - Investing.comJuly 5 at 11:58 AM | investing.comATHE Alterity Therapeutics Limited - Seeking AlphaJune 26, 2025 | seekingalpha.comIs Alterity Therapeutics Limited (ATHE) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comAlterity wins FDA fast-track for ATH434 – but with 9B shares on issue, impact dilutedMay 5, 2025 | msn.comAlterity Therapeutics Reveals Top Option HoldersApril 21, 2025 | tipranks.comAlterity Therapeutics completes placementApril 9, 2025 | uk.investing.comAlterity Therapeutics announces regulatory noticeApril 9, 2025 | uk.investing.comAlterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual MeetingApril 3, 2025 | markets.businessinsider.comAlterity Therapeutics completes last patient visit in ATH434-202 Phase 2 trialMarch 27, 2025 | markets.businessinsider.comAlterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to BillionairesMarch 10, 2025 | msn.comAlterity Therapeutics Ltd PBNMarch 1, 2025 | morningstar.comMAlterity Therapeutics Expands Capital with New Securities QuotationFebruary 18, 2025 | tipranks.comAlterity Therapeutics to List New Securities on ASXFebruary 16, 2025 | tipranks.comAlterity secures funding to advance MSA drug developmentFebruary 10, 2025 | msn.comAlterity Therapeutics raises A$40M in placementFebruary 10, 2025 | markets.businessinsider.comAlterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 yearFebruary 8, 2025 | finance.yahoo.comAlterity Therapeutics reports compliance with Takeovers PanelFebruary 5, 2025 | msn.comAlterity Therapeutics announces securities noticeFebruary 4, 2025 | msn.comAlterity Therapeutics Completes Significant Share IssuanceFebruary 3, 2025 | tipranks.comAlterity Therapeutics announces ATH434 Phase 2 trial resultsJanuary 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendTop 4 Growth Stocks With Momentum and Room to RunBy Ryan Hasson | June 16, 2025View Top 4 Growth Stocks With Momentum and Room to RunPRAN, BLRX, NTEC, NTRP, and ADXS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.12 0.00 (0.00%) As of 07/3/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.BioLineRx NASDAQ:BLRX$4.63 +0.02 (+0.43%) Closing price 07/3/2025 02:55 PM EasternExtended Trading$4.60 -0.04 (-0.76%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Intec Pharma NASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.NextTrip NASDAQ:NTRPNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Alterity Therapeutics NASDAQ:PRANAlterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story CAVA Group: Why the Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
